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Liver is an attractive organ for gene delivery in order to correct various genetic (metabolic) diseases.
Hydrodynamic vein injection of naked DNA/minicircles devoid of viral or plasmid backbones was demon-
strated in, for example, murine phenylketonuria to allow sustained therapeutic transduction of hepatocytes.
Herewe showsuccessful hepatocyte transfusion indomestic small pigs immediatelyafterweaninguponportal
vein catheterization and hydrodynamic injection of naked DNA/minicircle vectors expressing the luciferase
gene from the CMV or a liver-specific promoter. First, we established a surgical method allowing hydrody-
namic portal vein pressurization up to 120mmHg and infusion of naked DNA in pigs (n=5) with long-term
survival. No acute adverse effects such as changes in liver transaminases or signs of liver cell damage were
observed.We then showed efficiency of stable hepatocyte transfection at 10 and 28 days in single experiments
(n=7) where we found that up to 60% of samples (45/75) were polymerase chain reaction (PCR)-positive for
minicircle-DNA. Of these samples, 13% of the positive specimen (6/45) showed low but stable luciferase
expression when driven by a liver-specific promoter, as well as appropriate copy numbers per diploid genome.
In conclusion, we accomplished a safe procedure for stable transfection of liver cells upon hydrodynamic gene
delivery using minicircle vectors in small pigs as a prerequisite to potentially treat infants with genetic liver
diseases.
INTRODUCTION
NORMAL LIVER FUNCTION IS ESSENTIAL for the mam-
malian organism in multitudinous aspects. The
hepatic integrity can be threatened by a large va-
riety of acquired and inherited disorders; in the
former category, trauma, infections, cancer, auto-
immune disease, and many other disorders can
lead to hepatopathy. In addition, inherited dis-
eases can lead to impairment of any of the nu-
merous biochemical pathways located in the liver,
and some of these pathways are with respect to
pathophysiology even limited to this organ.1 An
example for the latter is the main pathway for
ammonia detoxification, the urea cycle, which is
composed of several consecutive enzymatic steps.2–4
Importantly, failure in just one step of this hepatic
pathway leads primarily to accumulation of neu-
rotoxic metabolites and brain dysfunction5–8 al-
though the defect is expressed only in the liver. The
presence of such disorders, with defects only in the
liver but severe sequelae for the entire body,makes
the liver a primary target organ for novel (not only)
gene therapeutic approaches.9,10
Currently available treatment modalities are, at
least in the case ofmetabolic liver disorders, far from
being satisfactory since they often address only the
symptoms of disease. In addition, several curative
approaches were evaluated such as transplantation
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of parts of the whole liver or of hepatocytes or of
hepatocyte-like cells derived from stem cells.11–13
While liver transplantation has proven beneficial for
a growing list of disorders, hepatocyte or stem cell
infusionsmay rather have a bridging than a curative
potential. As an alternative procedure, gene therapy
with different vector strategies was developed. Most
trials were undertaken with viral vectors that al-
lowed effective transfection of liver cells but raised
several concerns, including safety of repeated appli-
cations or of the risk formutagenesis. As a likely less
immunogenic approach, nonviral vectors were re-
cently introduced to the field of gene therapy.14,15
Nonviral vectors are circular naked DNA mole-
cules devoid of any viral or plasmid components
and require other routes of administration than
viral vectors in order to achieve sufficient rates
of transfection. Several studies in small rodents
(mice) have shown that hydrodynamic injections in
the tail vein allow for effective transduction of liver
cells (see for instance ref.16). If the liver is to be
addressed in larger animals or humans, hydrody-
namic injectionsmay require direct vascular access
via the portal or hepatic veins. Respective attempts
to prepare such interventions for use in human
patients have already been made in single large
animal studies where portal vein injections were
auspiciously applied in adult pigs or more recently
also in dogs.17–20 Previous interventions in human
newborns receiving hepatocyte transfusions were
done via access to the portal vein by surgical in-
sertion of a Hickman catheter into the middle colic
vein or by noninvasive interventional catheter
placement in the left portal vein branch.21 How-
ever, a direct surgical access by catheter placement
into the portal vein is a challenging procedure in
newborns and not at all yet part of clinical routine.
In this study, we test the hypothesis that our
successful hydrodynamic injection protocol of mini-
circles (MCs) in adult mice,16 done via the tail vein,
can be adapted to portal vein injections in small
domestic pigs immediately after weaning. We re-
gard this as a prerequisite before naked DNA can
be included in the armamentarium of gene ther-
apeutical approaches aiming for cure of genetically
determined liver diseases in newborns or infants
with inherited (metabolic) disorders that are lo-
cated in the periportal area of the liver (as it is the
case in urea cycle defects). The purpose of this
study was therefore to develop a safe surgical
method to performdirect hydrodynamic portal vein
injections of MCs in small pigs, to achieve long-
term survival of the animals, and to evaluate the
efficacy for clinical application of such an experi-
mental approach.
MATERIALS, METHODS, AND ANIMAL
HANDLING
Naked DNA/MC vectors
Purified MC vector MC.CMV-luc (3882bp) was
purchased from PlasmidFactory (Bielefeld, Ger-
many) harboring the firefly luciferase gene expressed
from the (nonliver specific) CMV promoter. A deriv-
ative MC vector MC.P3-luc (2324bp) expressing the
firefly luciferase from the liver-specific promoter
P316,22 was generated and purified according to a
previously published method.16,23 More detailed in-
formationonthisvectorcanbeobtaineduponrequest.
Animal handling
Animal experiments were performed in accor-
dance with the guidelines and policies of the Veter-
inary Office of the State of Zurich and Swiss law on
animal protection, the Swiss Federal Act on Animal
Protection (1978), and the Swiss Animal Protection
Ordinance (1981). Animal studies received approval
from the Cantonal Veterinary Office, Zurich, and
the Cantonal Committee for Animal Experiments,
Zurich, Switzerland (permission for animal experi-
ments Kt ZH 34-2013). Four-week-old female
domestic pigs (weight 3.6–7.5kg; Table 1) were
separated from their mothers immediately after
weaning and brought to a loose barn with porcine
mates 7 days before surgery.
Surgical procedures
A median laparotomy was performed, followed
by isolation of the different structures of the he-
patic ligament. The portal vein and hepatic arteries
were separated from the common bile duct. Then, a
circular suture (Prolene 7-0) was placed and a
portal venous cut down was performed in order to
place a 7 Fr two-lumen catheter directly into the
main portal vein. The position of the catheter was
ensured and corrected by radiography to place the
tip of the catheter into the main portal vein and
thus secure injection of MCs into the entire liver.
Table 1. Characteristics of pigs used for intraportal injections
of MC-DNA vectors
Pig no.a
Body weight
on surgery
day (kg)
Time of sacrifice
and sample
procurement (days)
Body
weight (kg) on
day of sacrifice
Liver weight (g)
on day
of sacrifice
A1 4.3 28 11.0 (day 28) 241
A2 4.8 28 10.0 (day 28) 254
B1 7.5 28 15.5 (day 28) 388
B2 7.0 28 15.0 (day 28) 406
C 5.6 10 8.8 (day 10) 246
D1 3.6 10 4.8 (day 10) 135
D2 7.0 10 n.d. (day 10) 400
n.d., not determined; MC, minicircles.
aFemale pigs.
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The catheter was tightly fixed by the circular su-
ture. For all experiments, clamps were placed at
the hepatic arteries and the portal vein distal from
the catheter allowing hepatic inflow obstruction
(Fig. 1A, C–F). Likewise, the suprahepatic inferior
cava vein was clamped in order to prevent venous
outflow from the liver during the injections ac-
cording to previous reports with adult pigs (Fig. 1A,
C–F).17,18 The total clamping time was kept short
(£10min) given the known vulnerability of the pig
intestine to outflow obstruction.
Establishment of intraportal injection
of small pigs
The surgical and injection procedures for portal
vein infusion were set up with five small female
pigs in acute studies; that is, animals were sacri-
ficed maximally 6hr after completion of the proce-
dure while still under deep anesthesia. Anesthesia
was introduced with propofol and sustained with
isoflurane during surgery. Continuous monitor-
ing including central venous pressure measure-
ment via the jugular vein, arterial blood pressure,
transcutaneous oxygen saturation, heart and re-
spiratory rates, and temperature was installed and
kept throughout the procedure. Intravascular
pressure in the main portal vein during hydrody-
namic injections was monitored via measurement
at the tip of one lumen of the catheter (Fig. 1B).
Placement of the catheter in the main portal vein
was controlled by angiography. During establish-
ment of hydrodynamic injections, flow rate, time,
and volume of the injections were modified with
flow rates between 10 and 20ml/sec and injection
time between 1 and 3 sec. The naked DNA/MC
vectors were diluted in 30ml of 0.9% normal saline
(Braun Medical AG, Sempach, Switzerland) for
adjusting concentrations as indicated. Final con-
ditions were controlled under angiography to doc-
ument optimized intrahepatic exposure time of the
injected solution.
When the procedure was established, we sub-
jected seven small female pigs immediately after
weaning to hydrodynamic portal vein infusionwith
luciferase-expressing MC vectors for chronic or
long-term expression studies (Tables 1 and 2). Pigs
A1 and A2 were injected with 0.44mg of MC.CMV-
luc, while pigs B1 and B2 were injected with a 10
times higher concentration (4.4mg), and pig Cwith
2mg of the sameMC vector. Whereas in pigs A and
B the flow rate of the injection was 20ml/sec, in pig
C a slower rate of 10ml/sec was used. The same
conditions were applied in pigs D1 and D2, which
were injected with 2mg of vector MC.P3-luc car-
rying the synthetic liver-specific promoter P3.16
It should be noted that the CMV promoter frag-
ment is roughly 1.9 kb, while the P3 promoter has a
length of 0.3 kb. In the following, we analyzed the
distribution and fate of MC-vector DNA, as well as
stable gene expression in the liver of these animals.
Postoperative monitoring
Animals were kept for 4 weeks (n=4) or 10 days
(n=3) after surgery.Liver transaminases (aspartate
aminotransferase, AST; alanine aminotransferase,
ALT), lactate dehydrogenase (LDH), and C-reactive
protein (CRP) were measured in the clinical chem-
istry laboratory at University Children’s Hospital
Zurich, Zurich, Switzerland, by automated analyzer
UniCel DXC600 (Beckman Coulter, Nyon, Switzer-
land) every week, except for pigs A, in which mea-
surements started on day 15 after surgery because
permission for collecting blood and urinewasnot yet
available. Baseline levels were obtained before sur-
gery (CRP was not measured at that time).
Collection of samples
Samples of blood and urine for monitoring of
standard biochemistry and for MC determination
were taken once a week under general anesthesia.
Pigs were sacrificed under general anesthesia with
propofol 10 days (n = 3) or 4 weeks (n = 4) after MC
injection. The entire liver was removed before col-
lection of 75 samples from all 5 lobes. Figure 2
shows the distribution of the 75 samples that were
collected and shock-frozen immediately after re-
section. In addition, samples from heart, spleen,
diaphragm, lung, and kidneys were collected and
stored shock-frozen. For histology of the liver, tis-
sue was fixed in formalin (4%). Following pro-
curement, liver samples were also stained for
hematoxylin–eosin (H&E) in order to analyze the
amount of necrosis at time of euthanasia.
Analysis of MC vector-DNA in pig liver
Liver tissue was homogenized using the Tissue-
Lyser II (Qiagen, Hombrechtikon, Switzerland).
DNA was extracted from liver homogenates using
the ‘‘DNeasy Blood and Tissue Kit’’ (Qiagen). This
kit was used as indicated in the manufacturer’s
protocol except for all steps before loading on the
membrane, where the amount of all fluids was
doubled. Purity and quality of DNAweremeasured
with NanoDrop ND1000 (Thermo Fisher Scien-
tific). Polymerase chain reaction (PCR) with DNA
isolated from the tissue samples was performed to
determine presence of MC. As forward primer 5¢-
CACGTTCGTCACATCTCATCTACC-3¢ (primer
f2 luc) and as reverse primer 5¢-TGAGCCCATATC
CTT GTC GTA TCC-3¢ (primer r2 luc) were used,
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Figure 1. Scheme of the portal vein access, pressure curve, and angiography. (A) Scheme of a liver with portal vein, hepatic arteries, and hepatic
veins, the latter leading to the inferior vena cava. For the hydrodynamic injection, the catheter was placed directly in the main trunk of the portal vein.
During the injection the portal vein, hepatic arteries and the suprahepatic inferior vena cava were clamped to allow pressure generation. (B) Pressure
curve for pig A2 as a representing example was plotted during hydrodynamic injection with a sensor at the tip of the catheter, confirming the fast and
significant increase of the portal vein pressure. (C–F) Contrast medium was injected by hydrodynamic injection in the same way as later for the chronic
experiments. Distal portal vein and hepatic arteries were clamped in all experiments for the duration of the injection. Pictures were taken from a film with
6 images/sec. (C) and (D) represent the situation from an experiment without clamping of the suprahepatic vena cava, while there was clamping of the
latter vein in the experiment shown in (E) and (F). (C) shows the distribution of contrast medium 2.5 sec after the injection limited to the liver. (D) Picture
taken 3.5 sec after the injection shows that a substantial portion of the contrast medium has already escaped to the right heart and pulmonary arteries.
(E) and (F), obtained 5 and 7 sec after the injection, demonstrate that clamping of the suprahepatic vena cava was efficient in preventing early loss of
the injected solution to the circulation. Color images available online at www.liebertpub.com/hgtb
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both of which binding specifically to the luciferase
gene on the MC.CMV-luc, while primer f2 luc and
reverse primer 5¢-TAG GCC CAT ATC CTT GCC
TGA TAC (primer r3 luc) were obtained to amplify
MC.P3-luc. PCR for 42 cycles using HOT FIREPol
polymerase (Solis BioDyne, Luzerne, Switzerland)
wasperformedatanannealing temperature of 58C.
The amplified fragment had an expected length of
533bp. As positive control we used DNA isolated
from wild-type mouse liver after hydrodynamic tail
vein injection16 with the MC.CMV-luc, which was
positive upon IVISanalysis (in vivo imaging system;
H.M. Viecelli and B. Tho¨ny, unpublished). PCR
products for both MC vectors (533bp) were control
sequenced using the BigDye Terminator cycle se-
quencing kit version 1.1 on a 3130/3130xl Genetic
Table 2. Portal pressure and flow rate during intraportal
MC-DNA injection, MC-vector type and amount,
and number of positive PCR samples
Pig no.
Maximum portal
pressure achieved
during MC
injectiona (mmHg)
Flow rate
(ml/sec);
injection
time (sec)
Injected
MC b (mg)
Number of
PCR-positive
liver samples
A1 89 20; 1.5 0.44 (MC.CMV-luc) 8/75 (11%)
A2 93 20; 1.5 0.44 (MC.CMV-luc) n.a.
B1 51 20; 1.5 4.4 (MC.CMV-luc) 19/75 (25%)
B2 n.d. 20; 1.5 4.4 (MC.CMV-luc) n.a.
C 21 10; 3 2.0 (MC.CMV-luc) 9/75 (12%)
D1 45 10; 3 2.0 (MC.P3-luc) 45/75 (60%)
D2 n.d. 10; 3 2.0 (MC.P3-luc) 36/75 (48%)
n.a., not analyzed; n.d., not determined because of technical problems
during injection; polymerase chain reaction, PCR.
aBaseline 5–12mmHg.
bThe size of MC vector MC.CMV-luc is 3882 bp, while that of MC.P3-luc is
2324 bp.
Figure 2. Anatomical sketches of pig liver lobes and efficacy of stable naked DNA/MC delivery and luciferase expression upon intraportal infusion. Drawing
of a caudal view on pig liver with position of the collected tissue samples indicated by white dots (if PCR-negative) or black dots (if PCR-positive); PCR-positive
samples that are positive also for luciferase activity are indicated by black dots encircled with yellow. (Pig A1) Results shown represent the findings in pig A1,
which was injected with 0.44mg of MC.CMV-luc and sacrificed 4 weeks after surgery. (Pig B1) Results shown represent the findings in pig B1, which was
injected with 4.4 mg of MC.CMV-luc and sacrificed 4 weeks after surgery. (Pig C) Results in pig C, which was injected with 2mg of MC.CMV-luc at slower
infusion rate than for pigs A and B (10ml/sec instead of 20ml/sec) and sacrificed 10 days after surgery. (Pig D1) Results in pig D1, which was injected with
2mg MC.P3-luc at an infusion rate of 10ml/sec and sacrificed 10 days after surgery. Color images available online at www.liebertpub.com/hgtb
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Analyzer (ABI sequencer; Applied Biosystems, Zug,
Switzerland). Forward and reverse primers were
used as described for PCR above. The received se-
quence was matched with the one of luciferase. The
same procedure was applied to samples from heart,
spleen, diaphragm, lung, and kidneys obtained
when animals were sacrificed.
Analysis of MC vector-DNA in pig blood
and urine
To investigate the MC latency in the porcine
organism and to determine the washout charac-
teristics ofMCs, blood and urine were investigated
at baseline and weekly after surgery until eutha-
nasia. Urine and plasma samples were directly
used as template for PCR without prior DNA iso-
lation. If urinary creatinine was above 7.6mM,
the sample was diluted with water to reach a
creatinine value below this threshold, which was
determined before by PCR of urine samples with
known creatinine levels (samples with a creati-
nine higher than the threshold inhibited the PCR
so that even positive samples yielded a negative
PCR result; data not shown). Plasma samples
were diluted 1:10 with water for the same reason
as described for the urine samples. Threshold was
determined by PCR of different dilutions of plas-
ma. PCR amplification was done as described
above. As a positive control, MCs in urine, plasma,
and water were amplified, and as a negative con-
trol, untreated urine and plasma was used. The
PCR products with a length of 533 bp were con-
firmed by sequencing as above.
Copy number assay
Genomic DNA (gDNA) from liver tissue was iso-
lated usingDNeasy blood and tissue kit (Qiagen). In
accordancewith themanufacturer’s protocol, 100ng
of gDNA from each sample was used as a template.
Standard curves plotting cycle threshold (Ct; y axis)
against log vector copy number (x axis) for each
vector infused in pig livers were generated using
serially diluted DNA vector with various copy
numbers (2 ·107 copies to 20 copies) with y =
-3.3x + 35.6, R2 =0.999 and y= -3.3x +37.7, R2 =
0.998 for MC.CMV-luc and MC.P3-luc, respec-
tively, along with 100ng noninfused control gDNA.
The number of vector genomes per cell in liver tis-
sue was determined by absolute quantitative PCR
analysis using TaqMan gene expression assay
corresponding to luciferase (Mr03987587_mr; Life
Technologies, Zug, Switzerland) in all liver tissue
samples that were positive in end-point (saturat-
ing) PCR. Quantitative PCRs were performed by
ABI PRISM 7900 sequence detector, and the data
were analyzed with Sequence Detection System
(Life Technologies). The haploid genome size of
pig is estimated to be 2800Mb (according to NCBI
Genome Database) and the mass of a single dip-
loid copy is 6.14 pg, which was calculated accord-
ing to the description from Life Technologies.
Therefore, the 100 ng gDNA contains 16,287 cop-
ies of diploid genome (1 · 105 pg/6.14 pg). The av-
erage transgene copy number in 100 ng gDNA in
each liver sample was then divided by 16,287 to
obtain the vector copy number in each cell. For
comparison to rodent liver, we injected a wild-type
C57BL/6 mouse with 15 lg of MC.P3-luc via hy-
drodynamic tail vein injection.16 The standard
curve with a serial dilution of known vector copy
numbers (2 · 107 copies to 20 copies) was = -3.0x +
38.8, R2 = 0.999.
Luciferase activity
To study expression levels of the naked DNA
injected, we measured luciferase activity in all
collected 75 liver samples. For this, we used the
Luciferase Assay System (Promega, Du¨bendorf,
Switzerland) on themicroplate reader infinite F 200
(Tecan, Ma¨nnedorf, Switzerland). For data analy-
ses, i-control 1.10 software (Tecan) was used. As a
positive control, liver tissue lysates from two PKU
mice injected with MC expressing luciferase were
used (not shown). As a negative control, a liver
tissue lysate of an untreated pig was taken.
RESULTS
Establishment of surgical procedures
for portal vein injections in small pigs
Based on what has been pioneered by others
performing hydrodynamic liver infusion of naked
DNA in adult pigs, we reasoned that a flow rate
between 10 and 20ml/sec, an injection volume of
30ml, and a vascular pressure in the portal vein
between 50 and maximally 120mmHg (baseline 5–
12mmHg) are considered to be optimal for small
pigs.18,24,25 Accordingly, the surgical procedures
and the required injection parameters were first
tested and established in small animals (n=5), and
thereafter applied in pigs with equal size for chronic
or long-term studies (n=7) of nakedDNA/MCvector
delivery by hydrodynamic portal vein injection
(see below). Importantly, all hemodynamic param-
eters during clamping of the liver remained nor-
mal. During the intraportal injection of 30ml
MC solution in 1.5 or 3 sec, the size of the liver in-
creased transiently and went back to normal within
a few seconds after opening the clamps, as reported
by others.18,24,25 In general, intravascular pres-
sure in the main portal vein during hydrodynamic
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injections was monitored via measurement at the
tip of the (two-lumen) catheter. Placement of the
catheter in the main portal vein was controlled un-
der angiography to document optimized in-
trahepatic exposure time of the injected solution
(Fig. 1C–F). Angiography allowed in addition to
follow theflow of contrastmediumunder exactly the
same injection conditions as later used in MC ex-
periments. Hereby, we saw, as expected, that
waiving of hepatic outflow clamping leads to disap-
pearance of contrast medium within few seconds
(Fig. 1C, D), while clamping of the suprahepatic
vena cava resulted in efficient sealing of hepatic
outflow without a need to clamp in addition the in-
frahepatic vena cava (Fig. 1E, F). Removal of the
catheter, recovery after surgery, and clinical moni-
toring during the postoperative period were un-
eventful in all pigs. Animals returned to a loose barn
with porcine mates within six hours after the end of
anesthesia. There were no complications regarding
wound healing and no need for medical interven-
tions during postoperative course, and animalswere
fed their normal diet upon return to their barn.
In conclusion, all small pigs included in this study
(total n=12), including the animals for the acute
study (n=5) as well as for chronic experiments
(n=7; see below), were stable during surgery, and
we did not observe any apparent adverse effect.
Detection of MC-DNA in pig liver after 10 days
and 4 weeks following portal vein infusion
Once we had established the basic conditions
for intraportal injections, we tested only a limited
number of small pigs for gene delivery using MC/
naked DNA vectors expressing luciferase either
from the CMV or the liver-specific promoter P316.
While a total of seven pigs were injected with dif-
ferent amounts ofMCvectors, liver tissue samples of
five pigs were analyzed in depths (A1, B1, C, D1, and
D2; see Tables 1–3 for the various characteristics).
Here we compared the effect of different amounts of
total DNA vector injected (0.44, 2, and 4.4mg) as
well as the two different promoters for luciferase
expression, CMV (1.9kb) and the liver-specific pro-
moter P3 (0.3kb), the latter used in two experiments
(pigs D1 and D2). Pressure monitoring showed that
in all pig livers, a substantial increase of the maxi-
mum portal pressure during injection was achieved
(Table 2). Besides the 75 tissue specimens re-
presenting all 5 liver lobes, samples from lung, kid-
ney, diaphragm, spleen, and heart were analyzed.
PCR products were validated by DNA sequence
analysis that confirmed the presence of the injected
luciferase gene (Fig. 3C). Tissue specimens from all
other organs were PCR-negative (not shown).
In liver, the number of positive samples varied
depending on the amount of MCs injected and the
flow rate or injection time. For instance, 4 weeks
after infusion, pig B1 with 4.4mg of vector DNA
resulted in double the amount of PCR-positive liver
samples (19/75=25%) as compared with pig A1
with 10 times less vector infused (0.44mg and 8/
75= 11% positive samples). The majority of the 19
positive samples (14/19) in pig B1 were located in
the left middle and left lower lobe (pig B1 in Fig. 2),
suggesting that the main part of the injected solu-
tion went to the respective liver lobes. Interest-
ingly, a prolonged injection time from 1.5 to 3 sec in
pig C compared with pig A1, while the injection
volume was identical, resulted in 4-fold lower por-
tal pressure but in a similar number of PCR-
positive liver samples as the amount of MC-vector
DNA was increased from 0.44mg in pig A1 to 2mg
in pig C. For pig D1 the same conditions were ap-
plied as in pig C but with the 40% shorter vector
MC.P3-luc; hence, an increased number of vector
molecules were injected. Here we found 60% (45/
75) of all liver samples to be positive 10 days after
infusion. Again, there was a skewed distribution of
positive samples with 100% positive specimens
taken from the left liver lobes and 33% positive
from the right and caudal lobes (pigD1 in Fig. 2). In
pig D2, the same conditions were applied as in pig
D1, resulting in 36/75 (48%) PCR-positive liver
Table 3. (A) Copy number per diploid genome in liver
of pigs infused with MC vectors, and (B) luciferase activity
in liver of pig D1 infused with 2mg of MC.P3-luc
(A) Vector genomes per diploid liver genome
Liver lobe
MC.CMV-luc MC.P3-luc
Pig A1
(0.44 mg)
Pig B1
(4.4 mg)
Pig C
(2.0 mg)
Pig D1
(2.0 mg)
Pig D2
(2.0 mg)
Right middle lobe n.d. 1.1 · 10-4 3.6· 10-5 1.2 · 10-3 4.0 · 10-4
Right lower lobe 6.9 · 10-7 1.8 · 10-4 4.2· 10-4 3.7 · 10-3 4.3 · 10-4
Left middle lobe 8.4 · 10-4 1.2 · 10-3 1.9· 10-5 1.8 · 10-1 1.6 · 10-4
Left lower lobe n.d. 4.3 · 10-4 1.4· 10-3 2.3 · 10-1 2.3 · 10-4
Caudal lobe 1.4 · 10-6 n.a. n.a. 1.8 · 10-3 3.8 · 10-4
(B) Luciferase expressed from a liver-specific promoter and vector copy
number in liver of pig D1
No. of liver sample
(according to
Fig. 2)
37 42 52 54 56 61
Luciferase activity
(RLU/lg protein)
8.42 3.11 1.52 1.52 6.25 1.06
Copy number per
diploid genome
1.5 · 10-1 9.9· 10-1 1.3 · 10-1 4.1 · 10-1 2.5 3.5 · 10-2
n.a., not analyzed for genome copy numbers as end-point (saturating)
PCR was negative; n.d., not detectable, represents a Ct value detected by
quantitative PCR that was higher than 35; RLU, relative light unit.
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samples in this animal that had even amuch larger
liver at the time of euthanasia (400 g in pig D2
compared with 135 g in pig D1; Table 1). Although
our observations are based on the limited number
of animals we were allowed to use for these studies,
we found stable liver transduction to be dependent
on the flow rate, on the amount of vector injected,
and/or on the MC vector size.
Analysis of MC-vector DNA in body
fluids of MC-transduced pigs
When plasma was investigated, MC-vector DNA
could be detected by PCR in samples obtained
directly after vector infusion but notwhen bloodwas
analyzed during postoperative monitoring or on the
day of sacrifice (Fig. 3A). The same was observed in
urine; that is, PCR-positive samples confirmed the
presence of MC-DNA in the urine collected 10min
afterMC-vector injection but sampleswere negative
thereafter during postoperative monitoring period
or upon sacrifice (Fig. 3B).
Impact of liver-targeted hydrodynamic gene
delivery on liver toxicity and histology
We examined acute and long-term liver toxicity
by enzyme marker activity and histological H&E
staining, respectively. All CRP values after injec-
tion remained normal (<4mg/liter). Furthermore,
neither acute adverse effects such as changes in
liver transaminases (AST and ALT) and LDH ac-
tivities as measured before and during the entire
postoperative monitoring (of 10 days or 4 weeks;
not shown), nor any signs of necrosis in resected
liver tissue were observed (Fig. 4). This confirmed
that the infusion procedure left a healthy and in-
tact liver in treated pigs, similarly as has been
described by others17,24 and to what we observed
for the mouse liver upon hydrodynamic tail vein
injection of MC-vectors.16
Luciferase activity and copy number
per diploid genome in liver
A quantitative assessment and correlation of
copy number per diploid genome with luciferase
Figure 3. Detection of MC-DNA by end-point PCR results in plasma, urine,
and liver upon MC-vector infusion. (A) Results of end-point PCR in plasma
showed a positive signal right after injection (0) but was negative for plasma
samples after 1, 2, 3, and 4weeks (exemplified for pig B1).Water (C) and plasma
from an untreated control pig (U) served as negative controls; MC.CMV-luc
added to a plasma sample served as positive control (P). (B) PCR in urine gave
the corresponding result to the plasmaPCR, as itwaspositive immediately after
injection (0) but no further positive results were found in urine samples after 1,
2, 3, and 4 weeks (exemplified for pig B2). Water (C) and untreated urine (U)
served as negative controls; MC.CMV-luc added to a urine sample served as
positive control (P). (C) PCR in liver DNA samples illustrating positive and
negative results (exemplified for pig B1). MC.P3-luc in mouse liver served as
positive control. (A–C) C, negative control (water); M, marker; P, positive
control; U, untreated sample (plasma or urine) as additional negative control.
Figure 4. Liver histology. Hematoxylin–eosin-stained liver tissue sample
obtained from pig B1 at the time of sacrifice at 28 days after vector DNA
infusion. There are no signs of necrosis in the liver tissue and histology
looks perfectly normal. The figure represents a 2.5-fold magnification. Color
images available online at www.liebertpub.com/hgtb
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activity in liver of pigs infused with the various
MC vectors is summarized in Table 3A and B.
With the exception of pig D1 (see below), all
vector genomes per diploid liver genome were
found to be 10-3 or lower, that is, undetectable in
some liver samples. Luciferase activity in repre-
sentative samples from each liver lobe in pigs A1,
B1, and C, each transduced with a construct
driving luciferase expression from the CMV pro-
moter, was negative, which was expected as the
CMV promoter does not sustain long-term ex-
pression and is eventually shut down in hepato-
cytes.26 In contrast, vector MC.P3-luc, expressing
luciferase from the strong liver-specific promoter
P3,22,16 resulted in low but stable transgene ex-
pression in pig D1 at least in both left lobes
where we found the highest vector copy numbers.
In detail, samples 37 and 42 within the left
middle lobe showed 8.42 and 3.11 RLU/lg pro-
tein, respectively, and in the left lower lobe, 4
samples showed luciferase activity (samples 52,
54, 56, and 61 showed 1.52, 1.52, 6.25, and 1.06
RLU/lg protein, respectively). All 75 samples
from pig D2, which received the same MC.P3-luc
as pig D1, had no stable luciferase expression at
10 days after injection because of the low copy
numbers that were comparable to pigs A1, B1, C,
and D1.
As we observed stable and long-term expression
of transgenes driven by the same liver-specific
promoter P3 upon hydrodynamic tail vein in-
jection of naked DNA/MC vectors in the mouse
liver16, we wanted to compare transfection effi-
ciency between mouse and pig liver. Our best re-
sults were obtained with pig D1, in which 2mg of
MC.P3-luc was injected into a whole liver of 135 g
(Table 1), which is equivalent to approximately
15 lg of vector DNA per gram of pig liver. We thus
injected a proportionate amount of MC.P3-luc into
a wild-type mouse, that is, 15 lg (with a liver of
1 g). Upon analysis of the whole mouse liver, we
found about 10 copies per diploid hepatocyte ge-
nome in the mouse with a luciferase activity of
5692 RLU/lg protein. As we observed in pig D1
samples (no. 42 or 54 in Table 3B) each approxi-
mately 3 RLU/lg protein and one vector copy per
diploid genome, that is, 10 times less genome
copies per hepatocyte than in our mouse infused
with the same vector, it can be estimated that
MC.P3-luc expressed the luciferase *600-fold
higher in murine than in pig hepatocytes. It re-
mains to be determined though whether this is
because of different promoter strength in the two
species or because of other factors that might in-
fluence transgene expression.
DISCUSSION
Metabolic liver disorders are often life-threatening
and curative therapies are scarce, rendering novel
therapies urgently needed. Already for almost
two decades, gene therapeutic approaches pro-
voked much hope, but only recent advances in the
field seem to justify the huge expectations.27
While most gene therapy trials use viral vectors to
transfect target cells, naked DNA/MCs were used
as an alternative to reduce immunogenic compli-
cations of repeated viral vector applications or the
risk of mutagenesis.14,15 As MCs do not contain
any bacterial or viral backbone, the safety of the
nonviral vectors outmatches viral vectors used far
more often for gene therapy until now. MCs can
therefore be regarded as an alternative to ‘‘clas-
sical’’ viral vector-based gene therapy offering
perspectives for many genetically determined
(liver) disorders, which currently lack curative
treatment.
However, since naked DNA lacks the natu-
ral capability of viral vectors to easily cross eu-
karyotic cell membranes, a different technical
approach is required in order to achieve sufficient
transfection of target cells.28 One alternative to
deliver naked DNA can be the application of a
high-pressure injection. In the case of murine
models, this was refined to the method of hydro-
dynamic tail vein injection, which was shown to
successfully lead to a long-term cure of a liver
metabolic disease, phenylketonuria (PKU), in a
murine model.16
We performed this study to transfer the afore-
mentioned successful method from mice to larger
animals in order to finally be able to treat humans,
or more specifically infants, rendering an alterna-
tive injection technique necessary since tail vein
injections are not feasible in humans. To develop
such method, we have chosen the pig model as
ideally suited since these animals feature a similar
anatomy, and have an immune system resembling
humansmore thanmice.29 Aswe intended to target
the liver, and here specifically the periportal he-
patocytes since several metabolic liver diseases are
exclusively expressed here, the injection of naked
DNA had thus to be transferred to a direct delivery
into the portal vein. The technique of hydrody-
namic injection into liver via portal or hepatic veins
was already used successfully in rabbits, dogs,
small pigs, larger (adult) pigs, and in humans (for a
recent overview discussion, see ref.19). Here we
successfully established, to our knowledge, for the
first time the procedure of hydrodynamic portal
vein injection in small pigs at the age of 4 weeks
immediately after weaning.
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The first challenge of hydrodynamic portal vein
injection in small pigs directly after weaning was
the size of the portal vein that required a thin
catheter still allowing sufficient flow volumes. As
this technique should eventually be established for
use in humannewborns or infants, establishing the
method under similar conditions seemed crucial.
Next to the establishment of a safe surgical cath-
eter placement into the main portal vein, a suffi-
cient hydrodynamic injection resulting in
significant increases of the portal vein pressure
had to be ensured in order to successfully transfer
MCs into the periportal liver cells. As described by
others,17,18,30 this was only achieved after block-
age of the vascular in- and outflow of the liver, a
procedure that was tolerated well in our pigs.
Thus, clamping of the portal vein distal to the in-
serted catheter, the hepatic artery, and the su-
prahepatic inferior vena cava was needed. Only if
this rigorous clamping was applied, a sufficient
increase of the pressure at the tip of the catheter
was achieved allowing the assumption of in-
creased intrahepatic pressure as also suggested
by swelling of the entire organ. Alternative vein
accesses were evaluated such as the splenic or
gastroepiploic vein; however, they showed no
permanent success rate, as depending on the an-
gle of the junction of the splenic and the portal
vein, it was often impossible to insert the catheter
properly.
While single variables of the procedure were
adapted during the study, the majority of the pa-
rameters were kept constant: in detail, (1) the age
of the animals at the time of surgery has been kept
constant as all were operated immediately after
weaning; (2) the weight of the animals was as
constant as possible in the given circumstances;
(3) the injection volume (30ml) was identical in all
animals; (4) there were only two different condi-
tions during injection, 20ml/sec in 1.5 sec or 10ml/
sec in 3 sec; (5) there were only two different vector
constructs used, either driven by a CMV promoter
or by the liver-specific promoter P3; (6) there were
only two time points for euthanasia (28 days or 10
days).
As demonstrated by PCR, an efficient transfec-
tion of liver cells was achieved by hydrodynamic
injection. This effect was dose dependent, as we saw
higher numbers of positive samples in animals in-
jected with higher doses of MCs. In addition, the
efficacy was dependent at least to some extent also
on the flow rate of infusion, as injection of pigs D1
andD2,whichwere injectedwith 2mgMC.P3-luc at
a flow rate of 10ml/sec, showed 60% and 48% PCR-
positive liver samples, respectively. This confirms
other reports of higher efficacy in experiments per-
formed at lower flow rates.30
Interestingly, the distribution of positive sam-
ples was shifted to the left liver lobes. Since
placement of the catheter within the main trunk of
the portal vein was confirmed by angiography, we
consider the skewed distribution as a result of the
high-pressure injection directing more of the MC
(and thus more DNA) to the left lobes of the liver
according to the anatomical composition of the
portal branches. An alternative explanation would
be that higher injection volumes would be needed
to achieve a more equal distribution.
Overall, the efficacy of our method needs to be
improved as reflected by the number of PCR-
negative samples. One reason for the limited effi-
cacy may be the too low amount of DNA injected,
as we found a dose-dependent transfection effi-
cacy. Alternatively, it may require a more pro-
longed injection pressure than just between 1.5
and 3 sec, as applied in our settings. According to
the experience made by others, our procedure of
intraportal high-pressure injection may still be
suboptimal with respect to the flow rate and vol-
ume, and the maximum pressure and time of the
injection.
To investigate whether there was any washout
of the injected MCs, we analyzed urine and blood
samples. To avoid loss of single MCs, we estab-
lished a method to subject urine and plasma di-
rectly as PCR template instead of the commonly
used DNA isolation protocols. We could confirm
reliable PCR amplification as long as the con-
centrations of PCR-inhibiting substances in the
specific body fluids are considered and samples
diluted accordingly. Since we did not detect MC-
DNA in any of the urine and plasma samples,
the positive results obtained in liver tissue reflect
MC survival within hepatocytes as degradation
occurs, as expected from previous studies, outside
cells. Importantly, all other organs apart from
liver were negative.
In addition to the presence of MC-DNA after 10
days and 4 weeks in all pigs investigated, we de-
tected a low but stable luciferase activity in samples
fromonly pigD1. Consistentwith this low luciferase
expression, quantitative PCR showed appropriate
copy numbers per diploid genome in liver samples
from pig D1. The low luciferase expression under-
lines our interpretation that themain future aim for
the hydrodynamic approach must be a further im-
provement of the methods’ efficacy. This is in par-
ticular advisable as experiments in mice show a
much better transduction efficacy as illustrated by
the higher copy numbers and higher levels of lucif-
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erase activity. In this context, one should emphasize
that the injection procedures were different in pigs
and in mice. This difference includes the injection
approach (portal vein in pigs and tail vein in mice),
the volume used for injections in comparison to body
weight (0.6% in pigs and 10% in mice), and the un-
known maximum pressure in mouse liver under
hydrodynamic tail vein injection. All these different
parameters make it difficult to compare results in
pigs with mice data.
Interestingly, pig D1 (and also pig D2) was
transduced with an MC vector expressing the lu-
ciferase from a strong liver-specific promoter,
which was not the case for other pigs that were
transfected with the non-liver-specific CMV pro-
moter. In mice, we observed shutdown of luciferase
expression from theCMVpromoter in the sameMC
vector in less than 10 days after hydrodynamic tail
vein injection (unpublished observation). Although
we have at this time no further data on the per-
formance in pig liver, we speculate that a CMV
promoter shutdown is likely to occur and might
explain the absence of luciferase expression in
those livers. Further experiments with liver-
specific promoters and other optimized constructs
will eventually show whether any transfected ac-
tivity will finally achieve therapeutic levels. As an
alternative to hydrodynamic injections, normody-
namic interventions applying encapsulation of
MCs can be considered.31
In conclusion, high-pressure portal vein injection
of MC DNA is a safe procedure in small pigs imme-
diately after weaning. Establishing this method in
pigs with a weight comparable to human newborns
should encourage re-evaluation of this method
also for human patients. The efficacy of the method,
however, needs to be increased in order to finally use
this method for therapeutic purposes. If the in-
traportal injection after reducing the invasiveness
and improving the efficacy still is safe, it might be-
come an auspicious therapy for several metabolic
liver disorders.
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